Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 10:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–113 of 113 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Polyposis Clear all
Not listed Phase 3 Interventional

Gel-Sinuplasty for Chronic Rhinosinusitis With and Without Nasal Polyposis

NCT03472144
View directory record Official record
Conditions
Chronic Sinusitis, Ethmoidal, Chronic Sinusitis - Ethmoidal Anterior, Chronic Sinusitis, Chronic Sinusitis - Ethmoidal, Posterior, Chronic Sinusitis, Sphenoidal, Chronic Sinusitis - Frontoethmoidal, Nasal Polyps, Nasal Polyp - Posterior
Interventions
gel loaded with steroids (momentasone), gel loaded with antibiotic (Levofloxacin), gel loaded with both steroids and antibiotic
Drug
Lead sponsor
LifeBridge Health
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 21, 2018 · Synced Oct 30, 2026, 10:37 AM EDT
Completed Phase 2 Interventional Results available

Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis

NCT00033371
View directory record Official record
Conditions
Colorectal Cancer, Familial Adenomatous Polyposis
Interventions
Celecoxib, Placebo, eflornithine, Laboratory biomarker analysis, Questionnaire administration
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 65 Years
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2020 · Synced Oct 30, 2026, 10:37 AM EDT
Recruiting Phase 1Phase 2 Interventional

FOG-001 in Locally Advanced or Metastatic Solid Tumors

NCT05919264
View directory record Official record
Conditions
Cancer, Colorectal Cancer, Solid Tumor, Locally Advanced Solid Tumor, Metastatic Cancer, WNT Pathway, HCC, Desmoid, Microsatellite Stable Colorectal Cancer, Metastatic Castration-resistant Prostate Cancer, Familial Adenomatous Polyposis (FAP), Endometrial Carcinoma, Prostate Cancer, Microsatellite Instability-High Colorectal Cancer, Adamantinomatous Craniopharyngioma
Interventions
FOG-001, mFOLFOX-6, Nivolumab, Trifluridine/tipiracil, Bevacizumab
Drug
Lead sponsor
Parabilis Medicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
619 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
31
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 30, 2026, 10:37 AM EDT
Completed Phase 3 Interventional

OPN-375 Efficacy and Safety in Adolescents With Bilateral Nasal Polyps

NCT03747458
View directory record Official record
Conditions
Bilateral Nasal Polyposis
Interventions
OPN-375
Drug
Lead sponsor
Optinose US Inc.
Industry
Eligibility
12 Years to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
22
States / cities
Gilbert, Arizona • Bakersfield, California • Fresno, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 30, 2026, 10:37 AM EDT
Recruiting Phase 3 Interventional

Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis

NCT06950385
View directory record Official record
Conditions
Familial Adenomatous Polyposis (FAP)
Interventions
eRapa (encapsulated rapamycin), Placebo
Drug
Lead sponsor
Rapamycin Holdings Inc.
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
18
States / cities
Arcadia, California • New Haven, Connecticut • Washington D.C., District of Columbia + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 30, 2026, 10:37 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Hereditary Gastric Cancer Syndromes: An Integrated Genomic and Clinicopathologic Study of the Predisposition to Gastric Cancer

NCT03030404
View directory record Official record
Conditions
Stomach Neoplasms, Stomach Cancer, Gastric Adenocarcinoma and Proximal Polyposis of the Stomach (GAPPS), Hereditary Diffuse Gastric Cancer (HDGC), Familial Diffuse Gastric Cancer
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years and older
Enrollment
733 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Oct 30, 2026, 10:37 AM EDT
Recruiting No phase listed Observational

A Personalized Surveillance and Intervention Protocol for Duodenal and Gastric Polyposis in Patients With Familial Adenomatous Polyposis

NCT04677998
View directory record Official record
Conditions
Familial Adenomatous Polyposis
Interventions
Personalized surveillance and intervention protocol
Procedure
Lead sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 30, 2026, 10:37 AM EDT
Terminated Not applicable Interventional Results available

An Evaluation of SprayShield in Reducing Post-Operative Adhesion Formation Following Major Open Abdominal Surgery

NCT01002287
View directory record Official record
Conditions
Ulcerative Colitis, Familial Polyposis
Interventions
SprayShield Adhesion Barrier System, Good Surgical Technique Alone
Device · Procedure
Lead sponsor
Integra LifeSciences Corporation
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Bedford, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 20, 2014 · Synced Oct 30, 2026, 10:37 AM EDT
Completed No phase listed Observational

Tissue Immune Interaction in Nasal Polyposis

NCT04628442
View directory record Official record
Conditions
Chronic Rhinosinusitis (Diagnosis), Chronic Rhinosinusitis With Nasal Polyps, Asthma
Interventions
Sinonasal Debridement Procedure, Nasal Polyp Removal, Biopsy
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 80 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Oct 30, 2026, 10:37 AM EDT
Active, not recruiting Phase 2 Interventional

Dupilumab Severe Eosinophilic Chronic Sinusitis Without Nasal Polyposis

NCT04430179
View directory record Official record
Conditions
Severe Eosinophilic Chronic Sinusitis Without Nasal Polyposis
Interventions
Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT], Placebo
Drug · Other
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 24, 2025 · Synced Oct 30, 2026, 10:37 AM EDT
Completed Early Phase 1 Interventional

Preclinical Studies of Omalizumab in Chronic Rhinosinusitis With Nasal Polyposis

NCT04583501
View directory record Official record
Conditions
Chronic Rhinosinusitis With Nasal Polyps, Nasal Polyps
Interventions
Omalizumab
Biological
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 13, 2024 · Synced Oct 30, 2026, 10:37 AM EDT
Enrolling by invitation No phase listed Observational

UC Davis Cohort of Pre-Malignant and Malignant Gastro-Intestinal DisEases Study

NCT05021029
View directory record Official record
Conditions
Intestinal Metaplasia, Chronic Gastritis, Atrophic Gastritis, Autoimmune Gastritis, Intestinal Dysplasia, Gastric Polyps
Interventions
Not listed
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 30, 2026, 10:37 AM EDT
Completed Phase 3 Interventional Results available

Nasal Packing as a Drug Delivery System Postoperatively in Chronic Sinusitis With Polyposis

NCT01197612
View directory record Official record
Conditions
Chronic Sinusitis, Polyposis
Interventions
pulmicort
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 99 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 29, 2018 · Synced Oct 30, 2026, 10:37 AM EDT
Terminated Phase 2 Interventional

Testing Obeticholic Acid for Familial Adenomatous Polyposis

NCT05223036
View directory record Official record
Conditions
Attenuated Familial Adenomatous Polyposis, Colorectal Carcinoma, Duodenal Carcinoma, Familial Adenomatous Polyposis
Interventions
Biopsy Procedure, Biospecimen Collection, Gastrointestinal Endoscopy, Obeticholic Acid, Placebo Administration, Questionnaire Administration
Procedure · Biological · Drug + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
6
States / cities
Scottsdale, Arizona • Kansas City, Kansas • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 30, 2026, 10:37 AM EDT
Completed Not applicable Interventional Results available

CryoBalloon Ablation for Treatment of Duodenal Adenomas

NCT03847636
View directory record Official record
Conditions
Duodenal Adenomas, Familial Adenomatous Polyposis
Interventions
CryoBalloon ablation
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
4
States / cities
Baltimore, Maryland • Manhasset, New York • Danville, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 30, 2026, 10:37 AM EDT
Active, not recruiting No phase listed Observational

Dupilumab Treatment Effects in an Ethnically Diverse Population With Chronic Rhinosinusitis With Nasal Polyposis

NCT05246267
View directory record Official record
Conditions
Chronic Rhinosinusitis With Nasal Polyps
Interventions
Dupilumab
Biological
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 30, 2026, 10:37 AM EDT
Completed Phase 2 Interventional Results available

Trial of eRapa to Prevent Progression in Familial Adenomatous Polyposis Patients Under Active Surveillance

NCT04230499
View directory record Official record
Conditions
Familial Adenomatous Polyposis
Interventions
Encapsulated Rapamycin (eRapa)
Drug
Lead sponsor
Rapamycin Holdings Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
4
States / cities
Ann Arbor, Michigan • Cleveland, Ohio • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 30, 2026, 10:37 AM EDT